(Total Views: 323)
Posted On: 11/21/2019 7:09:27 AM
Post# of 153969
Yes, that's an important difference, since the early-stage space has become quite crowded by now (and it would probably take us 5 years to get approval).
It would be more interesting to go to the later stages of the disease where there is unmet medicial need (NASH fibrosis and cirrhosis) and where, with great results, we could qualify for accelerated approval.
NP is only hinting at that. Though it seems like he is equating the general term NAFLD with stage 1, since he is making a contrast with NASH patients (Stage 2).
"We are very excited to see more evidence showing that leronlimab may play a critical role in slowing or reversing disease progression in NAFLD and potentially NASH patients,"
We need some clarification here.
It would be more interesting to go to the later stages of the disease where there is unmet medicial need (NASH fibrosis and cirrhosis) and where, with great results, we could qualify for accelerated approval.
NP is only hinting at that. Though it seems like he is equating the general term NAFLD with stage 1, since he is making a contrast with NASH patients (Stage 2).
"We are very excited to see more evidence showing that leronlimab may play a critical role in slowing or reversing disease progression in NAFLD and potentially NASH patients,"
We need some clarification here.
(0)
(0)
